Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HMGCR | P04035 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | CPT2 | P23786 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | ACLY | P53396 | 3/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16418496 | 0.90 | CYP2C19 (0.44) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL28312 | 0.82 | ALDH1A1 (0.53) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL16418481 | 0.80 | TSHR (0.37) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL16418483 | 0.80 | CYP2C19 (0.37) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL17480770 | 0.80 | ALDH1A1 (0.46) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL3178813 | 0.78 | CYP2D6 (0.48) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL20360428 | 0.77 | HMGCR (0.48) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL7237685 | 0.76 | ALDH1A1 (0.51) | CYP2C19HIF1ACYP2D6ALDH1A1KDM4E | |
| SCHEMBL29152296 | 0.76 | CYP2D6 (0.46) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 | |
| SCHEMBL29152298 | 0.76 | CYP2D6 (0.46) | CYP2C19HIF1ACYP2D6TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207865-B | Plasticizer composition, resin composition and method for preparing the same | LG化学株式会社 | 2025-03-07 | — | — | CN | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2024-01-25 | — | — | US | disclosed |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2023-09-21 | — | — | US | disclosed |
| US-20170233443-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2017-08-17 | — | — | US | disclosed |
| US-9683019-B2 | Cyclic polypeptides for the treatment of heart failure | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-20170119851-A1 | METHODS OF TREATING ANOREXIA | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
| US-20160166634-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | NOVARTIS AG (CH) | 2016-06-16 | — | — | US | disclosed |
| US-9340582-B2 | Bioconjugates of synthetic apelin polypeptides | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-20160108091-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
| US-9266925-B2 | Cyclic polypeptides for the treatment of heart failure | NOVARTIS AG (CH) | 2016-02-23 | — | — | US | disclosed |
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | NOVARTIS AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
| US-20150030594-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | NOVARTIS AG (CH) | 2015-01-29 | — | — | US | disclosed |
| EP-1112245-A1 | METHOD FOR PRODUCING GAMMA,DELTA-UNSATURATED KETONES BY CARROLL-REACTION | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000014046-A1 | METHOD FOR PRODUCING η,δ-UNSATURATED KETONES BY CARROLL-REACTION | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030585-A1 | NOVEL FATTY ACIDS AND THEIR USE IN CONJUGATION TO BIOMOLECULES | FABP1, FABP2, FABP3 | CYP2C19 1501/4885HIF1A 1358/4885CYP2D6 2119/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | CYP2C19 3711/4885HIF1A 4229/4885CYP2D6 2261/4885 |
| US-20150031604-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | CYP2C19 2026/4885HIF1A 734/4885CYP2D6 2010/4885 |
| US-20230295322-A1 | BINDING MOLECULES AGAINST BCMA AND USES THEREOF | EPCAM, CD40, BCR | CYP2C19 3963/4885HIF1A 2685/4885CYP2D6 2629/4885 |
| US-20170119851-A1 | METHODS OF TREATING ANOREXIA | CRH, VIP, GIPR | CYP2C19 4657/4885HIF1A 184/4885CYP2D6 4784/4885 |
| US-20170233443-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | CYP2C19 2026/4885HIF1A 734/4885CYP2D6 2010/4885 |
| US-20240025993-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | CYP2C19 1357/4885HIF1A 4614/4885CYP2D6 3046/4885 |
| US-20160166634-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | APLNR, AP1G1, VIP | CYP2C19 2290/4885HIF1A 1054/4885CYP2D6 1490/4885 |
| US-20160108091-A1 | CYCLIC POLYPEPTIDES FOR THE TREATMENT OF HEART FAILURE | NPY1R, ACKR3, IAPP | CYP2C19 2026/4885HIF1A 734/4885CYP2D6 2010/4885 |
| US-20150030594-A1 | BIOCONJUGATES OF SYNTHETIC APELIN POLYPEPTIDES | APLNR, AP1G1, VIP | CYP2C19 2290/4885HIF1A 1054/4885CYP2D6 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.